Advertisement

Topics

Cerecor Inc. Company Profile

01:03 EDT 19th September 2018 | BioPortfolio

Driven by an innovative team of industry experts and leading scientists, Cerecor aspires to develop neuroscience drugs that will make a difference. We are committed to improving the lives of patients by addressing underserved segments of common diseases. We are focused exclusively on developing products that have human proof-of-concept in either the target or the molecule and possess biomarkers to guide development, and our clinical strategies employ the latest technologies to improve the likelihood of trial success. www.cerecor.com


News Articles [12 Associated News Articles listed on BioPortfolio]

Management tracks: Cerecor, Sangamo

Cerecor appoints Peter Greenleaf CEO

Cerecor Announces Expansion of Leadership Team

New Leadership Supports Company Evolution into Innovative Specialty Pharmaceutical Company BALTIMORE, July 16, 2018 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ:CERC), today announced executive manag...

Cerecor Reports Second Quarter 2018 Financial Results

BALTIMORE, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), an integrated biopharmaceutical company focused on pediatric healthcare and developing innovative therapies that make a dif...

Cerecor Reports First Quarter 2018 Financial Results

BALTIMORE, May 11, 2018 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ:CERC) (“Cerecor” or the “Company”) today announced financial results for the first quarter of 2018. Net revenues for the fir...

Cerecor CEO to Present at the H.C. Wainwright Global Investment Conference

BALTIMORE, Aug. 31, 2018 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on the near-term goal of becoming a leader in the U.S. pediatric market space, today an...

Cerecor Announces First Patient Enrolled in Phase I Trial for Neurogenic Orthostatic Hypotension (nOH) in Parkinson’s Disease

Study to evaluate safety, tolerability and effects on blood pressure of CERC-301 in patients with nOH BALTIMORE, Md., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), today announce...

Cerecor Appoints Simon Pedder to its Board of Directors

BALTIMORE, MD--(Marketwired - April 09, 2018) - Cerecor, Inc. (NASDAQ: CERC), today announced that Simon C. Pedder, Ph.D. has been appointed to its Board of Directors. "We are delighted to welcome D...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

Cerecor Inc.

Driven by an innovative team of industry experts and leading scientists, Cerecor aspires to develop neuroscience drugs that will make a difference. We are committed to improving t...

More Information about "Cerecor Inc." on BioPortfolio

We have published hundreds of Cerecor Inc. news stories on BioPortfolio along with dozens of Cerecor Inc. Clinical Trials and PubMed Articles about Cerecor Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cerecor Inc. Companies in our database. You can also find out about relevant Cerecor Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record